Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in non-obese adolescents and women

Human Reproduction Update

Volumn 12, Issue 3, 2006, Pages 243-252

  Ibáñez, Lourdes ^a   de Zegher, Francis ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Drospirenone; Flutamide; Metformin; Oral contraception; Polycystic ovary syndrome

Indexed keywords

CYPROTERONE ACETATE; DROSPIRENONE; ETHINYLESTRADIOL; FLUTAMIDE; GESTODENE; METFORMIN; ORAL CONTRACEPTIVE AGENT; SPIRONOLACTONE;

ACNE; ADOLESCENT; ADULT; BODY MASS; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; EMBRYOTOXICITY; FEMALE; HIRSUTISM; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; LIVER DYSFUNCTION; LIVER TOXICITY; LOW DRUG DOSE; MENSTRUAL IRREGULARITY; NEUTROPHIL COUNT; OBESITY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; REVIEW; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY;

ADOLESCENT; ADULT; ANDROGEN ANTAGONISTS; ANDROSTENES; CONTRACEPTIVES, ORAL; DRUG THERAPY, COMBINATION; FEMALE; FLUTAMIDE; HUMANS; HYPERANDROGENISM; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; METFORMIN; POLYCYSTIC OVARY SYNDROME;

EID: 33645801997     PISSN: 13554786     EISSN: 14602369     Source Type: Journal    
DOI: 10.1093/humupd/dmi054     Document Type: Review

References (76)

1. Abbott DH, Barnett DK, Bruns CM and Dumesic DA (2005) Androgen excess fetal programming of female reproduction: A developmental aetiology for polycystic ovary syndrome? Hum Reprod Update 11,357-374.
2. Andrade RJ, Lucena MI, Fernandez MC, Suarez F, Montero JL, Fraga E and Hidalgo F (1999) Fulminant liver failure associated with flutamide therapy for hirsutism. Lancet 353,983.
3. Asunción M, Calvo RM, San Millan JL, Sancho J, Avila S and Escobar-Morreale H (2000) A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 85,2434-2438.
4. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES and Yildiz BO (2004a) The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89,2745-2749.
5. Azziz R, Sanchez LA, Knochenhauer ES, Moran C, Lazenby J, Stephens KC, Taylor K and Boots LR (2004b) Androgen excess in women: Experience with over 1000 consecutive patients. J Clin Endocrinol Metab 89,453-462.
6. Azziz R, Marin C, Hoq L, Badamgarav E and Song P (2005) Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. J Clin Endocrinol Metab 90,4650-4658.
7. Baumann EE and Rosenfield RL (2002) Polycystic ovary syndrome in adolescence. Endocrinologist 12,333-348.
8. Boulman N, Levy Y, Leiba R, Shachar S, Linn R, Zinder O and Blumenfeld Z (2004) Increased C-reactive protein levels in the polycystic ovary syndrome: A marker of cardiovascular disease. J Clin Endocrinol Metab 89,2160-2165.
9. Buggs C and Rosenfield RL (2005) Polycystic ovary syndrome in adolescence. Endocrinol Metab Clin North Am 34,677-705.
10. Cheang KI and Nestler JE (2004) Should insulin-sensitizing drugs be used in the treatment of polycystic ovary syndrome? Reprod Biomed Online 8,440-447.
11. Checa MA, Requena A, Salvador C, Tur R, Callejo J, Espinos JJ, Fabregues F and Herrero J (2005) Insulin-sensitizing agents: Use in pregnancy and as therapy in polycystic ovary syndrome. Hum Reprod Update 11,375-390.
12. Cibula D, Fanta M, Vrbikoba J, Stanicka S, Dvorakova K, Hill M, Skrha J, Zivny J and Skrenkova J (2005) The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenemia, SHBG and lipids in PCOS patients. Hum Reprod 20,180-184.
13. Cusan L, Dupont A, Gomez JL, Tremblay RR and Labrie F (1994) Comparison of flutamide and spironolactone in the treatment of hirsutism: A randomized controlled trial. Fertil Steril 61,281-287.
14. Diamanti-Kandarakis E, Mitrakou A, Hennes MM, Platanissiotis D, Kaklas N, Spina J, Georgiadou E, Hoffmann RG, Kissebah AH and Raptis S (1995) Insulin sensitivity and antiandrogenic therapy in women with polycystic ovary syndrome. Metabolism 44,525-531.
15. Diamanti-Kandarakis E, Mitrakou A, Raptis S, Tolis G and Duleba AJ (1998) The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome. J Clin Endocrinol Metab 83,2699-2705.
16. Diamanti-Kandarakis E, Baillargeon JP, Iuorno MJ, Jakubowicz DJ and Nestler JE (2003) A modern medical quandary: Polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. J Clin Endocrinol Metab 88,1927-1932.
17. Dunaif A and Thomas A (2000) Current concepts in the polycystic ovary syndrome. Annu Rev Med 52,401-419.
18. Dunaif A, Hoffman AR, Scully RE, Flier JS, Longcope C, Levy LJ and Crowley WF Jr (1985) Clinical, biochemical, and ovarian morphologic features in women with acanthosis nigricans and masculinization. Obstet Gynecol 66,545-552.
19. Elter K, Imir G and Durmusoglu F (2002) Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovary syndrome: A randomized controlled study. Hum Reprod 17,1729-1737.
20. Fernández-Real JM, Broch M, Ricart W, Casamitjana R, Gutiérrez C, Vendrell J and Richart C (1998) Plasma levels of the soluble fraction of tumor necrosis factor receptor 2 and insulin resistance. Diabetes 47,1757-1762.
21. Gambineri A, Pelusi C, Genghini S, Morselli-Labate AM, Cacciari M, Pagotto U and Pasquali R (2004) Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin Endocrinol 60,241-249.
22. Goldstein BJ and Scalia R (2004) Adiponectin: A novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab 87,2870-2874.
23. Gomez JL, Dupont A, Cusan L, Tremblay M, Suburu R, Lemay M and Labrie F (1992) Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients. Am J Med 92,465-470.
24. Gonzalez F, Minium J, Rote NS and Kirwan JP (2005) Hyperglycemia alters tumor necrosis factor-alpha release from mononuclear cells in women with polycystic ovary syndrome. J Clin Endocrinol Metab 90,5336-5342.
25. Ibáñez L and de Zegher F (2003a) Flutamide-metformin to reduce fat mass in hyperinsulinemic ovarian hyperandrogenism: Effects in adolescents and in women on third-generation oral contraception. J Clin Endocrinol Metab 88, 4720-4724.
26. Ibáñez L and de Zegher F (2003b) Low-dose combination of flutamide, metformin and an oral contraceptive for non-obese, young women with polycystic ovary syndrome. Hum Reprod 18,57-60.
27. Ibáñez L and de Zegher F (2004a) Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and young women with hyperinsulinemic hyper-androgenism: Opposite effects on adipocytokines and body adiposity. J Clin Endocrinol Metab 89,1592-1597.
28. Ibáñez L and de Zegher F (2004b) Flutamide-metformin plus an oral contraceptive (OC) for young women with polycystic ovary syndrome: switch from third- to fourth-generation OC reduces body adiposity. Hum Reprod 19,1725-1727.
29. Ibáñez L and de Zegher F (2005) Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and anti-atherogenesis in young women with ovarian hyperandrogenism: The key role of metformin at start and after more than one year of therapy. J Clin Endocrinol Metab 90,39-43.
30. Ibáñez L, de Zegher F, Francois I and Potau N (1998) Precocious pubarche, hyperinsulinism and ovarian hyperandrogenism in girls: relation to reduced fetal growth. J Clin Endocrinol Metab 83,3558-3662.
31. Ibáñez L, Potau N, Marcos MV and de Zegher F (2000a) Treatment of hirsutism, hyper-androgenism, oligomenorrhea, dyslipidemia, and hyperinsulinism in nonobese, adolescent girls: Effect of flutamide. J Clin Endocrinol Metab 85,3251-3255.
32. Ibáñez L, Valls C, Potau N, Marcos MV and de Zegher F (2000b) Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. J Clin Endocrinol Metab 85,3526-3530.
33. Ibáñez L, Valls C, Potau N, Marcos MV and de Zegher F (2001) Polycystic ovary syndrome after precocious pubarche: Ontogeny of the low birth-weight effect. Clin Endocrinol 55,667-672.
34. Ibáñez L, Valls C, Ferrer A, Ong K, Dunger D and de Zegher F (2002) Additive effects of insulin-sensitizing and antiandrogen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia and anovulation. J Clin Endocrinol Metab 87,2870-2874.
35. Ibáñez L, Ong K, Ferrer A, Amin R, Dunger D and de Zegher F (2003) Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in non-obese adolescents and young women with ovarian hyperandrogenism. J Clin Endocrinol Metab 88,2600-2606.
36. Ibáñez L, Valls C, Cabré S and de Zegher F (2004a) Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and anti-atherogenesis in young women with ovarian hyperandrogenism: The key role of early, low-dose flutamide. J Clin Endocrinol Metab 89,4716-4720.
37. Ibáñez L, Ferrer A, Ong K, Amin R, Dunger D and de Zegher F (2004b) Insulin sensitization early post-menarche prevents progression from precocious pubarche to polycystic ovary syndrome. J Pediatr 144,23-29.
38. Ibáñez L, Valls C, Marcos MV, Ong K, Dunger D and de Zegher F (2004c) Insulin sensitization for girls with precocious pubarche and with risk for polycystic ovary syndrome: Effects of prepubertal initiation and postpubertal discontinuation of metformin. J Clin Endocrinol Metab 89,4331-4337.
39. Ibáñez L, Jaramillo A, Ferrer A and de Zegher F (2005a) Absence of hepatotoxicity after long-term, low-dose flutamide in hyperandrogenic girls and young women. Hum Reprod 20,1833-1836.
40. Ibáñez L, Jaramillo A, Ferrer A and de Zegher F (2005b) High neutrophil count in girls and women with hyperinsulinemic hyperandrogenism: Normalization with metformin and flutamide overcomes the aggravation by oral contraception. Hum Reprod 20,2457-2462.
41. Ibáñez L, Valls C and de Zegher F (2005c) Discontinuous flutamide-metformin plus an oral or a transdermal contraceptive in patients with hyperinsulinemic hyperandrogenism: Normalizing effects on C-reactive protein, tumor necrosis factor-α and the neutrophil/ lymphocyte ratio. Hum Reprod. Epub ahead of print October 20, 2005.
42. Kashyap S, Wells GA and Rosenwaks Z (2004) Insulin-sensitizing agents as primary therapy for patients with polycystic ovarian syndrome. Hum Reprod 11,2474-2483.
43. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM and Sattar N (2001) Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 86,2453-2455.
44. Kirchengast S and Huber J (2001) Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Hum Reprod 16,1255-1260.
45. La Marca A, Carducci Artensio A, Stabile G and Volpe A (2005) Metformin treatment of PCOS during adolescence and the reproductive period. Eur J Obstet Gynecol Reprod Biol 121,3-7.
46. Labrie F, Dupont A, Giguere M, Borsanyi JP, Lacourciere Y, Belanger A, Lachance R, Emond J and Monfette G (1988) Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): The minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer. Prog Clin Biol Res 260,41-62.
47. Lord JM, Flight IH and Norman RJ (2003) Metformin in polycystic ovary syndrome: Systematic review and meta-analysis. BMJ 327,951-953.
48. Luthy IA, Begin DJ and Labrie F (1988) Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture. J Steroid Biochem 31,845-852.
49. Mastorakos G, Koliopoulos C and Creatsas G (2002) Androgen and lipid profiles in adolescent girls with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives. Fertil Steril 77,919-927.
50. Mitkov M, Pehlivanov B and Terzieva D (2005) Combined use of metformin and ethinyl-estradiol-cyproterone acetate in polycystic ovary syndrome. Eur J Obstet Gynecol 118,209-213.
51. Morin-Papunen L, Rautio K, Ruokonen A, Hedberg P, Puukka M and Tapanainen JS (2003a) Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88,4649-4654.
52. Morin-Papunen L, Vauhkonen I, Koivunen R, Ruokonen A, Martikainen H and Tapanainen JS (2003b) Metformin versus ethinylestradiol-cyproterone acetate in the treatment of non-obese women with polycystic ovary syndrome: A randomized study. J Clin Endocrinol Metab 88,148-156.
53. Muderris II, Bayram F and Guven M (2000) Treatment of hirsutism with lowest-dose flutamide (62.5 mg/day). Gynecol Endocrinol 14,38-41.
54. Nestler JE (2001) Metformin and the polycystic ovary syndrome. J Clin Endocrinol Metab 86,1430.
55. Orio F Jr, Palomba S, Cascella T, De Simone B, Di Biase S, Russo T, Labella D, Zullo F, Lombardi G and Colao A (2004) Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab 89,4588-4593.
56. Orio F Jr, Palomba S, Cascella T, Di Biase S, Manguso F, Tauchmanova L, Nardo LG, Labella D, Savastano S, Russo T et al. (2005) The increase of leukocytes as a new putative marker of low grade chronic inflammation and early cardiovascular risk in the polycystic ovary syndrome. J Clin Endocrimol Metab 90,2-5.
57. Poyet P and Labrie F (1985) Comparison of the antiandrogenic/androgenic activities of flutamide, cyproterone acetate and megestrol acetate. Mol Cell Endocrinol 42,283-288.
58. Rautio K, Tapanainen JS, Ruokonen A and Morin-Papunen L (2005) Effects of metformin and ethinyl-estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome. Eur J Endocrinol 152,269-275.
59. Rexrode KM, Pradhan A, Manson JE, Buring JE and Ridker PM (2003) Relationship of total and abdominal adiposity with CRP and IL-6 in women. Ann Epidemiol 13,674-682.
60. Sahin I, Serter R, Karakurt F, Demirbas B, Culha C, Taskapan C, Kosar F and Aral Y (2004) Metformin versus flutamide in the treatment of metabolic consequences of non-obese young women with polycystic ovary syndrome: A randomized prospective study. Gynecol Endocrinol 19,115-124.
61. Seto-Young D, Paliou M, Schlosser J, Avtanski D, Park A, Patel P, Holcomb K, Chang P and Poretsky L (2005) Direct thiazolidinedione action in the human ovary: Insulin-independent and insulin-sensitizing effects on steroidogenesis and insulin-like growth factor binding protein-1 (IGFBP-1) production. J Clin Endocrinol Metab 90,6099-6105.
62. Singh SM, Gauthier S and Labrie F (2000) Androgen receptor antagonists (antiandrogens): Structure-activity relationships. Curr Med Chem 7,211-247.
63. Sjöholm A and Nyström T (2005) Endothelial inflammation and insulin resistance. Lancet 365,610-612.
64. Stein IF and Leventhal ML (1935) Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 29,181-191.
65. Stout DL and Fugate SE (2005) Thiazolidinediones for treatment of polycystic ovary syndrome. Pharmacotherapy 25,244-252.
66. Tarkun I, Arslan BC, Canturk Z, Turemen E, Sahin T and Duman C (2004) Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. J Clin Endocrinol Metab 89,5592-5596.
67. Tarkun I, Cetinarslan B, Turemen E, Sahin T, Canturk Z and Komsuoglu B (2005) Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial function in non-obese young women with polycystic ovary syndrome. Eur J Endocrinol 153,115-121.
68. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19,41-47.
69. Thole Z, Manso G, Salgueiro E, Revuelta P and Hidalgo A (2004) Hepatotoxicity induced by antiandrogens: A review of the literature. Urol Int 73,289-295.
70. Velazquez EM, Mendoza S, Hamer T, Sosa F and Glueck CJ (1994) Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 43,647-654.
71. Venturoli S, Paradisi R, Bagnoli A, Colombo FM, Ravaioli B, Vianello F, Mancini F, Gualerzi B, Porcu E and Seracchioli R (2001) Low-dose flutamide (125 mg/day) as maintenance therapy in the treatment of hirsutism. Horm Res 56,25-31.
72. Vrbikova J and Cibula D (2005) Combined oral contraceptives in the treatment of polycystic ovary syndrome. Hum Reprod Update 11,277-291.
73. Vural B, Caliskan E, Turkoz E, Kilic T and Demirci A (2005) Evaluation of metabolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome. Hum Reprod 20,2409-2413.
74. Wallace C, Lalor EA and Chik CL (1993) Hepatotoxicity complicating flutamide treatment of hirsutism. Ann Intern Med 119,1150.
75. Wysowski DK and Fourcroy JL (1996) Flutamide hepatotoxicity. J Urol 155,209-212.
76. Wysowski DK, Freiman JP, Tourtelot JB and Horton ML 3rd (1993) Fatal and nonfatal hepatotoxicity associated with flutamide. Ann Intern Med 118,860-864.